|Bid||0.00 x 1000|
|Ask||0.00 x 1200|
|Day's Range||44.67 - 48.59|
|52 Week Range||39.16 - 77.63|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||48.08|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.00|
In this article I am going to calculate the intrinsic value of Quidel Corporation (NASDAQ:QDEL) by taking the expected future cash flows and discounting them to their present value. I Read More...
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will hold a conference call on December 10, 2018 to discuss the San Diego Superior Court’s ruling related to Quidel’s BNP Supply Agreement with Beckman. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Monday, December 10th to discuss the outcome. Quidel’s responses to these questions, as well as other matters discussed during the conference call, may contain or constitute material information that has not been previously disclosed.
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the San Diego Superior Court (the “Court”) stated that it intends to enter an order granting Beckman’s motion for summary adjudication relating to the agreement for the supply of antibodies and other inputs related to, and distribution of, the Triage® BNP Test for the Beckman Coulter Access Family of Immunoassay Systems, between Quidel and Beckman (the “Beckman Agreement”). Specifically, the Court stated that it intends to rule that a provision of the Beckman Agreement restricting Beckman from manufacturing or selling another BNP or NT-proBNP assay is void as a matter of law.
Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.
Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.
Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received CE Mark for its TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be used as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel’s Triage® MeterPro instrumented system. MI, or heart attack, occurs when a part of the heart muscle doesn’t receive enough blood flow.
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the 30th Annual Piper Jaffray Healthcare Conference, to be held at the Lotte New York Palace hotel in New York, New York on Wednesday, November 28, 2018. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) with a question and answer session scheduled during the presentation.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
Quidel (QDEL) delivered earnings and revenue surprises of 18.00% and -2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had net income of 27 cents per share. Earnings, adjusted for one-time gains and costs, came to 59 cents per share. The results topped Wall Street expectations. The average ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended September 30, 2018.
Quidel (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.